文献速递泌尿生殖与妇科肿瘤放疗放疗物理与技术

直肠间隔水凝胶用于大体积前列腺(>80 cc)的可行性与剂量学结果

Expanding the Utilization of Rectal Spacer Hydrogel for Larger Prostate Glands (>80 cc): Feasibility and Dosimetric Outcomes.
PubMed 文献 · Adv Radiat Oncol · 2021-01-16

本研究评估直肠周围水凝胶间隔在前列腺体积>80 cm³患者中的可行性与剂量学结果。33例患者(平均108.1 cm³)接受水凝胶置入,中位随访10个月,所有患者耐受良好,未观察到急性≥2级胃肠道不良事件,剂量学结果良好。

要点

  • 前列腺>80 cm³患者置入水凝胶间隔可行,剂量学结果良好。
  • 中位直肠-前列腺水凝胶间隔为9.3 mm(范围4.7-19.4 mm)。
  • 未观察到急性≥2级胃肠道不良事件。

核心结论

  • 水凝胶置入在前列腺体积>80 cm³患者中可行,且剂量学结果良好。

研究设计与样本

  • 单中心研究,2017年1月至2019年12月纳入33例前列腺体积>80 cm³的前列腺癌患者,平均体积108.1 cm³(范围81.1-186.6 cm³),其中15例体积>80至100 cm³,18例>100 cm³。
  • 中位随访10个月(范围3-26个月),中位国际前列腺症状评分为9(范围1-18)。
  • 所有患者均在局部麻醉下置入水凝胶;15例接受调强放射治疗,18例接受质子治疗;21例靶区为前列腺+精囊腺,12例另接受选择性淋巴结照射。
  • 16例接受常规分割至78 Gy/39次,17例接受中度大分割至70 Gy/28次。

主要发现

  • 常规分割组平均直肠V75、V70、V60、V50分别为0.87%、2.25%、5.61%、10.5%。
  • 常规分割组中,前列腺体积>80至100 cm³和>100 cm³者的直肠V70分别为2.55%和2%。
  • 大分割组平均直肠V65、V63、V60、V50分别为1.67%、2.3%、3.4%、8.6%。
  • 大分割组中,前列腺体积>80至100 cm³和>100 cm³者的直肠V63分别为2%和2.56%。
  • 总体平均腺体中段直肠-前列腺水凝胶间隔为9.3 mm(范围4.7-19.4 mm)。

临床怎么用

  • 对于前列腺体积>80 cm³的前列腺癌患者,可考虑在局部麻醉下置入直肠间隔水凝胶,以获得有利的剂量学结果并降低直肠受量。

局限性

  • 样本量较小(33例),中位随访时间较短(10个月),仅报告急性毒性。
  • 未设对照组,剂量学比较缺乏对照。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

PURPOSE: The Hydrogel Spacer Prospective Randomized Pivotal Trial achieved mean rectoprostatic spacing of 12.6 mm resulting in lowering of rectal V70 from 12.4% (without spacer) to 3.3% (with spacer) in patients with glands up to 80 cm3. The value of this approach in patients with larger glands is inadequately established. This study assesses the feasibility and dosimetric outcomes of perirectal spacing in patients with prostate cancer with larger glands (>80 cm3). METHODS AND MATERIALS: Between January 2017 and December 2019, 33 patients with prostate glands >80 cm3 (mean 108.1 cm3; range, 81.1-186.6 cm3) were treated, 15 with glands >80 to 100 cm3 and 18 >100 cm3. Median follow-up was 10 months (range, 3-26). The median international prostate symptom score was 9 (range, 1-18). Hydrogel was placed under local anesthesia in all cases. Treatment modality included intensity modulated radiation therapy in 15 and proton therapy (PT) in 18 patients. Treatment targeted the prostate plus seminal vesicles in 21 patients and 12 also had elective nodal irradiation. Conventional fractionation (CF) to 78 Gy in 39 fractions was used in 16 and moderate hypofractionation (HF) to 70 Gy in 28 fractions in 17 patients. RESULTS: In the CF group, mean rectum (r) V75, 70, 60, 50 was 0.87%, 2.25%, 5.61%, and 10.5%, respectively. For glands >80 to 100 cm3 and >100 cm3, rV70 was 2.55% and 2%, respectively. In HF patients, mean rV65, 63, 60, and 50 was 1.67%, 2.3%, 3.4%, and 8.6%. For glands >80 to 100 cm3 and >100 cm3, rV63 was 2% and 2.56%, respectively. Overall, the mean midgland rectoprostatic hydrogel separation was 9.3 mm (range, 4.7-19.4 mm). All patients tolerated treatment well; no acute grade 2 or higher adverse gastrointestinal events were observed. CONCLUSIONS: Hydrogel placement is feasible in prostate glands larger than 80 cm3 with favorable dosimetric outcomes.

来源:Adv Radiat Oncol,查看原文。版权归原作者所有。

引用

  1. Fagundes M, Rodrigues MA, Olszewski S, et al. Expanding the Utilization of Rectal Spacer Hydrogel for Larger Prostate Glands (>80 cc): Feasibility and Dosimetric Outcomes. Adv Radiat Oncol. 2021. PMID: 34195489. doi:10.1016/j.adro.2021.100651

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。